Home › Blood Cancers › NCT07403812

Assessing DCog Short for Neurotoxicity in CAR-T

Assessing the Performance of "DCog Short", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
* Visual acuity of 20/100 or better.

Exclusion Criteria:

* patients \< 18 years old
* pregnant women
* prisoners
* adults unable to consent,
* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

About the study

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

What is being tested

• DCog Short (behavioral)

Sponsor: Beth Israel Deaconess Medical Center · Participants: 40 · Started: Apr 13, 2026

Contact the study team

• Jon Arnason, MD · Phone: (617) 667-9920

Official record on ClinicalTrials.gov — NCT07403812

Locations in the U.S.

Conditions

• Blood Cancers

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.